TWI449535B - 針對類澱粉- β肽之抗體於治療年齡相關黃班退化之用途 - Google Patents

針對類澱粉- β肽之抗體於治療年齡相關黃班退化之用途 Download PDF

Info

Publication number
TWI449535B
TWI449535B TW097108208A TW97108208A TWI449535B TW I449535 B TWI449535 B TW I449535B TW 097108208 A TW097108208 A TW 097108208A TW 97108208 A TW97108208 A TW 97108208A TW I449535 B TWI449535 B TW I449535B
Authority
TW
Taiwan
Prior art keywords
antibody
antibodies
amino acid
peptide
binding
Prior art date
Application number
TW097108208A
Other languages
English (en)
Chinese (zh)
Other versions
TW200900079A (en
Inventor
Chia Yang Lin
Original Assignee
Rinat Neuroscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rinat Neuroscience Corp filed Critical Rinat Neuroscience Corp
Publication of TW200900079A publication Critical patent/TW200900079A/zh
Application granted granted Critical
Publication of TWI449535B publication Critical patent/TWI449535B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW097108208A 2007-03-09 2008-03-07 針對類澱粉- β肽之抗體於治療年齡相關黃班退化之用途 TWI449535B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89418107P 2007-03-09 2007-03-09
US12/041,581 US20090022728A1 (en) 2007-03-09 2008-03-03 Methods of treating ophthalmic diseases

Publications (2)

Publication Number Publication Date
TW200900079A TW200900079A (en) 2009-01-01
TWI449535B true TWI449535B (zh) 2014-08-21

Family

ID=39760152

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097108208A TWI449535B (zh) 2007-03-09 2008-03-07 針對類澱粉- β肽之抗體於治療年齡相關黃班退化之用途

Country Status (15)

Country Link
US (1) US20090022728A1 (fr)
EP (1) EP2134751A2 (fr)
JP (2) JP5964004B2 (fr)
KR (2) KR101259225B1 (fr)
CN (2) CN101687922B (fr)
AU (1) AU2008224600B2 (fr)
BR (1) BRPI0808711A2 (fr)
CA (1) CA2680222C (fr)
HK (1) HK1201046A1 (fr)
IL (1) IL200528A0 (fr)
MX (1) MX2009009636A (fr)
NZ (1) NZ579273A (fr)
RU (1) RU2434639C2 (fr)
TW (1) TWI449535B (fr)
WO (1) WO2008110885A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
PL2046833T3 (pl) 2006-07-14 2014-01-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
NZ601858A (en) * 2007-10-05 2014-03-28 Genentech Inc Methods and compositions for diagnosis and treatment of amyloidosis
AU2015200604B2 (en) * 2007-10-05 2016-10-27 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
CA2701790A1 (fr) * 2007-10-05 2009-04-16 Ac Immune S.A. Utilisation d'anticorps anti-amyloides beta humanises dans les maladies oculaires
US9403902B2 (en) * 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
PE20091449A1 (es) * 2007-12-11 2009-10-07 Glaxo Group Ltd Proteinas de union a antigenos
JP2013523182A (ja) 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
JP6081356B2 (ja) 2010-07-30 2017-02-15 エーシー イミューン エス．エー． 安全で機能的なヒト化抗βアミロイド抗体
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
US20140050733A1 (en) 2011-02-07 2014-02-20 Dale B. Schenk Apoe immunotherapy
RU169012U1 (ru) * 2016-08-08 2017-03-01 Дмитрий Викторович Давыдов Электрод для электростимуляции зрительного нерва и зрительных путей и контроля физиологических параметров орбитальных структур глаза
WO2018200620A1 (fr) * 2017-04-25 2018-11-01 National Cheng Kung University Utilisation d'antagonistes de l'il-20 pour le traitement de maladies oculaires
MX2022007114A (es) * 2019-12-09 2022-07-11 Alexion Pharma Inc Polipeptidos de fosfatasa alcalina y metodos de uso de los mismos.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060057701A1 (en) * 2004-07-30 2006-03-16 Arnon Rosenthal Antibodies directed against amyloid-beta peptide and methods using same
US20060121039A1 (en) * 2004-12-07 2006-06-08 Alcon, Inc. Use of agents that prevent the generation of amyloid-like proteins and/or drusen, and/or use of agents that promote sequestration and/or degradation of, and/or prevent the neurotoxic effects of such proteins in the treatment of macular degeneration

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005025516A2 (fr) * 2003-09-12 2005-03-24 The Regents Of The University Of California Anticorps monoclonaux specifiques a des intermediaires d'agregation de poids moleculaire eleve communs a des amyloides formes a partir de proteines de sequence differente
EP1633786A4 (fr) * 2002-10-09 2007-07-25 Rinat Neuroscience Corp Methodes de traitement de la maladie d'alzheimer au moyen d'anticorps diriges contre le peptide g(b)-amyloide et compositions les comprenant
WO2006039327A2 (fr) * 2004-10-01 2006-04-13 Merck & Co., Inc. Procedes de traitement ou prophylaxie de maladies amyloidogeniques de l'oeil ou du nerf optique
AU2006211625A1 (en) * 2005-01-14 2006-08-10 The Regents Of The University Of California Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
UY29504A1 (es) * 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
RU2551782C2 (ru) * 2005-12-12 2015-05-27 Ац Иммуне Са Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами
PL2046833T3 (pl) * 2006-07-14 2014-01-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
EP2074145B1 (fr) * 2006-10-02 2017-08-16 AC Immune S.A. Anticorps humanise contre amyloide-beta

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060057701A1 (en) * 2004-07-30 2006-03-16 Arnon Rosenthal Antibodies directed against amyloid-beta peptide and methods using same
US20060121039A1 (en) * 2004-12-07 2006-06-08 Alcon, Inc. Use of agents that prevent the generation of amyloid-like proteins and/or drusen, and/or use of agents that promote sequestration and/or degradation of, and/or prevent the neurotoxic effects of such proteins in the treatment of macular degeneration

Also Published As

Publication number Publication date
CA2680222A1 (fr) 2008-09-18
CN101687922B (zh) 2014-06-11
KR101259225B1 (ko) 2013-04-30
JP2009062358A (ja) 2009-03-26
MX2009009636A (es) 2009-12-11
CA2680222C (fr) 2013-10-08
CN101687922A (zh) 2010-03-31
NZ579273A (en) 2012-03-30
RU2009133789A (ru) 2011-03-20
KR20090119990A (ko) 2009-11-23
EP2134751A2 (fr) 2009-12-23
WO2008110885A3 (fr) 2009-01-15
IL200528A0 (en) 2010-04-29
BRPI0808711A2 (pt) 2014-08-12
WO2008110885A2 (fr) 2008-09-18
AU2008224600B2 (en) 2011-09-29
AU2008224600A1 (en) 2008-09-18
TW200900079A (en) 2009-01-01
CN104027803A (zh) 2014-09-10
US20090022728A1 (en) 2009-01-22
RU2434639C2 (ru) 2011-11-27
KR20120054105A (ko) 2012-05-29
HK1201046A1 (en) 2015-08-21
JP2015038109A (ja) 2015-02-26
JP5964004B2 (ja) 2016-08-03

Similar Documents

Publication Publication Date Title
TWI449535B (zh) 針對類澱粉- β肽之抗體於治療年齡相關黃班退化之用途
JP5042828B2 (ja) アミロイド−ベータ・ペプチドに対して向けられる抗体、および該抗体を用いる方法
AU2006242546B2 (en) Antibodies directed against amyloid-beta peptide and methods using same
KR20020089359A (ko) Ａβ 펩티드를 격리시키는 인간화 항체
EP2200699A1 (fr) Protéines de liaison aux antigènes
AU2010279892B8 (en) Humanized anti-amyloid-b oligomer antibody

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees